Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension

Phase 3

Completed

• Conditions: Hypertension
• Interventions: Drug: Low dose of losartan; Drug: Low dose of telmisartan; Drug: High dose of telmisartan; Drug: High dose of losartan

• Registration Number: NCT02269176
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

Using Losartan as a comparator, to evaluate the efficacy and safety of telmisartan in the treatment of the mild to moderate primary hypertension patients in China

Detailed Description

Not available

Study Timeline

• Study Start: 2000-07
• Primary Completion: 2001-01
• Status Verified: 2014-10
• Study First Submitted: 2014-10-20
• Study First Submitted QC: 2014-10-20
• Last Update Submitted: 2014-10-20
• Study First Posted: 2014-10-21
• Last Update Posted: 2014-10-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 330

Inclusion Criteria

• Mild to moderate primary hypertension, the mean sitting valley value of diastolic blood pressure (DBP) ≥ 95 and < 110 mmHg, and the mean sitting valley value of systolic blood pressure (SBP) < 180 mmHg

Exclusion Criteria

• Not specified

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Losartan	Low dose of losartan	Low dose of losartan, uptitrated to high dose in case no sufficient effect is observered
Telmisartan	Low dose of telmisartan	Low dose of telmisartan, uptitrated to high dose in case no sufficient effect is observered
Telmisartan	High dose of telmisartan	Low dose of telmisartan, uptitrated to high dose in case no sufficient effect is observered
Losartan	High dose of losartan	Low dose of losartan, uptitrated to high dose in case no sufficient effect is observered

Primary Outcome Measures

Name	Time	Method
Changes in mean sitting valley value of DBP	8 weeks after start of treatment	The valley value of blood pressure refers to the blood pressure measured prior to the next administration of antihypertensives